Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA Approves 1st New Schizophrenia Drug in Decades
In a Victory for the Free Market, FDA Approves New Schizophrenia Drug
Despite billions of taxpayer dollars spent on mental illness research, Cobenfy was developed by a private biopharmaceutical company.
US FDA approves GE HealthCare's diagnostic drug for heart disease
The U.S. Food and Drug Administration approved GE HealthCare's diagnostic drug for use in detection of coronary artery disease, the company said on Friday.
FDA Approves New Kind of Drug for Schizophrenia
FRIDAY, Sept. 27, 2024 (HealthDay News) -- The first new type of medication in decades to help fight against schizophrenia was approved on Thursday by the U.S. Food and Drug Administration.
FDA issues recall notices over 2 brands of pet food
FDA Alert: Dog Food Recall Over Salmonella, Listeria Fears — What Owners Must Do Now
Certain lots of Answers dog food and Darwin's Natural Pet Products, which includes dog and cat food, have been recalled after the FDA tested samples of the brand's pet food, which tested positive for salmonella and listeria. So far, no illnesses related to the recall have been reported, according to the FDA's press release.
ANSWERS Pet Food recalled over salmonella, listeria concerns: What pet owners need to know
ANSWERS Pet Food is voluntarily recalling several of its products due to potential salmonella and listeria exposure, according to the FDA.
FDA issues recall notices over 2 brands of pet food due to salmonella and listeria risk
Answers Pet Food and Darwin’s Natural Pet Products, were found to have produced pet food that was contaminated with the bacteria salmonella and listeria, which can cause illness in pets that can then infect their owners.
FDA Lifts Clinical Hold On BMF-219
US FDA lifts clinical hold on Biomea's diabetes trials after safety review
The U.S. Food and Drug Administration lifted a clinical hold on Biomea Fusion's ongoing studies of its experimental drug for type 1 and type 2 diabetes, the drug developer said on Thursday. The regulator had placed a hold on two trials of its lead drug,
Biomea Fusion : FDA Lifts Clinical Hold On BMF-219 For Type 1 And Type 2 Diabetes Trials; Stock Up
Biomea Fusion Inc. (BMEA) announced that the U.S. Food and Drug Administration has lifted the clinical hold on the company's ongoing
Biomea Fusion: FDA Lifts Hold on Diabetes-Treatment Trials
Biomea Fusion said the Food and Drug Administration lifted its clinical hold on continuing clinical trials of the company's diabetes drug. The FDA in June put the biopharmaceutical company's trials on hold,
Opinion
6h
on MSN
Opinion
Column: A federal appeals court hands the FDA a stupendous win in its battle against stem cell clinics
Just as it began to seem that the battle against pseudoscience in medicine was being lost, a federal appeals court in San ...
12h
on MSN
US FDA approves Sanofi-Regeneron's Dupixent for 'smoker's lung'
The U.S. Food and Drug Administration has approved Sanofi and Regeneron's blockbuster drug Dupixent for patients with a ...
STAT
6h
The FDA is ‘making sandwiches,’ ‘breakfast salad’ in DC, and what keeps us from choking on food
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. In a new ...
1d
FDA approves new schizophrenia drug
The U.S. Food and Drug Administration has approved a new drug for adults with schizophrenia, the FDA announced Thursday.
Courthouse News Service
4h
Ninth Circuit sides with FDA in oversight of ‘liquid magic’ stem cell therapy
The panel agreed with the FDA that the treatment in which a patient's tissue is processed doesn't fall under the same ...
JD Supra
8h
FDA Issues Multiple Guidances Supporting Clinical Trial Innovation
In September 2024, the U.S. Food and Drug Administration (FDA) issued three guidance documents to support different clinical ...
MedPage Today
11h
COVID Preventive Drug Should Work Against Circulating Variants, FDA Now Says
The FDA has determined that the monoclonal antibody pemivibart (Pemgarda) is likely to be effective against currently ...
Medscape
12h
FDA OKs First-in-Class Antipsychotic for Schizophrenia
The FDA has approved a first-in-class antipsychotic that targets cholinergic receptors without blocking dopamine receptors.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Food and Drug Administration
Schizophrenia
Regeneron
Dupixent
Cobenfy
Feedback